JP2012502938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502938A5 JP2012502938A5 JP2011527243A JP2011527243A JP2012502938A5 JP 2012502938 A5 JP2012502938 A5 JP 2012502938A5 JP 2011527243 A JP2011527243 A JP 2011527243A JP 2011527243 A JP2011527243 A JP 2011527243A JP 2012502938 A5 JP2012502938 A5 JP 2012502938A5
- Authority
- JP
- Japan
- Prior art keywords
- dsm
- cancer
- antibody
- cell
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025598 Malignant hydatidiform mole Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000008824 placental choriocarcinoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 claims 1
- 101000677540 Homo sapiens Acetyl-CoA carboxylase 2 Proteins 0.000 claims 1
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000005757 colony formation Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000002147 killing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000005909 tumor killing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9745308P | 2008-09-16 | 2008-09-16 | |
| EP08016277A EP2166021A1 (en) | 2008-09-16 | 2008-09-16 | Monoclonal antibodies for treatment of cancer |
| US61/097,453 | 2008-09-16 | ||
| EP08016277.9 | 2008-09-16 | ||
| PCT/EP2009/006704 WO2010031551A2 (en) | 2008-09-16 | 2009-09-16 | Monoclonal antibodies for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502938A JP2012502938A (ja) | 2012-02-02 |
| JP2012502938A5 true JP2012502938A5 (enExample) | 2012-10-25 |
Family
ID=40589589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527243A Pending JP2012502938A (ja) | 2008-09-16 | 2009-09-16 | 癌の治療のためのモノクローナル抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8946388B2 (enExample) |
| EP (3) | EP2166021A1 (enExample) |
| JP (1) | JP2012502938A (enExample) |
| KR (1) | KR101818741B1 (enExample) |
| CN (3) | CN104628858B (enExample) |
| AU (1) | AU2009294896B2 (enExample) |
| BR (1) | BRPI0918178B8 (enExample) |
| CA (1) | CA2732594C (enExample) |
| CY (1) | CY1119956T1 (enExample) |
| DK (1) | DK2342234T3 (enExample) |
| ES (1) | ES2659718T3 (enExample) |
| HK (1) | HK1253579A1 (enExample) |
| HR (1) | HRP20180262T1 (enExample) |
| HU (1) | HUE036477T2 (enExample) |
| IL (2) | IL211010A (enExample) |
| LT (1) | LT2342234T (enExample) |
| MX (2) | MX357010B (enExample) |
| NO (1) | NO2342234T3 (enExample) |
| NZ (2) | NZ591004A (enExample) |
| PL (1) | PL2342234T3 (enExample) |
| PT (1) | PT2342234T (enExample) |
| RS (1) | RS56937B1 (enExample) |
| SI (1) | SI2342234T1 (enExample) |
| SM (1) | SMT201800079T1 (enExample) |
| TR (1) | TR201802090T4 (enExample) |
| WO (1) | WO2010031551A2 (enExample) |
| ZA (1) | ZA201100835B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| EP1970384A1 (en) | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| CA2696627C (en) | 2007-08-17 | 2016-09-27 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| EP3508498A1 (en) * | 2011-01-19 | 2019-07-10 | Cantargia AB | Novel agents and uses thereof |
| US20130236890A1 (en) * | 2012-03-08 | 2013-09-12 | HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH | Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells |
| KR101471253B1 (ko) * | 2012-10-29 | 2014-12-10 | 인제대학교 산학협력단 | 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| KR102354613B1 (ko) | 2012-11-15 | 2022-01-21 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| WO2015172800A1 (en) * | 2014-05-12 | 2015-11-19 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
| HUE066137T2 (hu) | 2013-10-18 | 2024-07-28 | Novartis Ag | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére |
| JP6464166B2 (ja) | 2013-11-14 | 2019-02-06 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 陽電子放出断層撮影用の化合物 |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| JP6901400B2 (ja) * | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
| RU2729396C2 (ru) * | 2015-07-14 | 2020-08-06 | МЕДИММЬЮН, ЭлЭлСи | Композиции и способы лечения рака |
| HK1258125A1 (zh) | 2015-09-04 | 2019-11-08 | The California Institute For Biomedical Research | 胰岛素免疫球蛋白融合蛋白 |
| MX2018006333A (es) * | 2015-12-01 | 2018-08-01 | Genmab Bv | Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. |
| WO2018075857A1 (en) | 2016-10-20 | 2018-04-26 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN106632661A (zh) * | 2017-01-10 | 2017-05-10 | 天津东亚生物技术有限公司 | 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用 |
| EP3597735A4 (en) * | 2017-03-15 | 2020-11-25 | Suzhou Galaxy Biopharma, Co., Ltd. | CTLA4 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USES THEREOF |
| CN107556369A (zh) * | 2017-08-23 | 2018-01-09 | 天津国际生物医药联合研究院 | 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用 |
| CA3097381A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| CN109402064B (zh) * | 2018-11-05 | 2021-05-14 | 湖南省肿瘤医院 | 杂交瘤细胞株及其产生的单克隆抗体和应用 |
| CN120097930A (zh) | 2019-05-20 | 2025-06-06 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| KR102266418B1 (ko) * | 2019-07-30 | 2021-06-16 | 한국생명공학연구원 | 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US5744585A (en) | 1995-03-16 | 1998-04-28 | Medenica; Rajko D. | Human monoclonal antibody against lung carcinoma |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20020065394A1 (en) * | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2634294A1 (en) | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003075014A2 (en) | 2002-03-06 | 2003-09-12 | Oxford Glycosciences (Uk) Ltd | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CN101245376A (zh) | 2003-01-17 | 2008-08-20 | 香港中文大学 | 作为妊娠相关病症的诊断标志物的循环mRNA |
| US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| CN1663603A (zh) | 2004-03-02 | 2005-09-07 | 北京大学 | 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用 |
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| HRP20231525T1 (hr) | 2009-02-20 | 2024-03-15 | Astellas Pharma Inc. | Postupci i pripravci za dijagnozu i liječenje raka |
| EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
-
2008
- 2008-09-16 EP EP08016277A patent/EP2166021A1/en not_active Withdrawn
-
2009
- 2009-09-16 KR KR1020117007149A patent/KR101818741B1/ko not_active Expired - Fee Related
- 2009-09-16 NZ NZ591004A patent/NZ591004A/en not_active IP Right Cessation
- 2009-09-16 SI SI200931801T patent/SI2342234T1/en unknown
- 2009-09-16 US US13/119,027 patent/US8946388B2/en not_active Expired - Fee Related
- 2009-09-16 NZ NZ596490A patent/NZ596490A/xx not_active IP Right Cessation
- 2009-09-16 MX MX2015005367A patent/MX357010B/es unknown
- 2009-09-16 HR HRP20180262TT patent/HRP20180262T1/hr unknown
- 2009-09-16 MX MX2011002856A patent/MX2011002856A/es active IP Right Grant
- 2009-09-16 CN CN201410649373.1A patent/CN104628858B/zh not_active Expired - Fee Related
- 2009-09-16 RS RS20180160A patent/RS56937B1/sr unknown
- 2009-09-16 BR BRPI0918178A patent/BRPI0918178B8/pt not_active IP Right Cessation
- 2009-09-16 NO NO09778564A patent/NO2342234T3/no unknown
- 2009-09-16 DK DK09778564.6T patent/DK2342234T3/en active
- 2009-09-16 JP JP2011527243A patent/JP2012502938A/ja active Pending
- 2009-09-16 CN CN200980136101.9A patent/CN102164963B/zh not_active Expired - Fee Related
- 2009-09-16 EP EP17201134.8A patent/EP3312198A1/en not_active Withdrawn
- 2009-09-16 ES ES09778564.6T patent/ES2659718T3/es active Active
- 2009-09-16 HU HUE09778564A patent/HUE036477T2/hu unknown
- 2009-09-16 PT PT97785646T patent/PT2342234T/pt unknown
- 2009-09-16 AU AU2009294896A patent/AU2009294896B2/en not_active Ceased
- 2009-09-16 WO PCT/EP2009/006704 patent/WO2010031551A2/en not_active Ceased
- 2009-09-16 TR TR2018/02090T patent/TR201802090T4/tr unknown
- 2009-09-16 SM SM20180079T patent/SMT201800079T1/it unknown
- 2009-09-16 LT LTEP09778564.6T patent/LT2342234T/lt unknown
- 2009-09-16 CA CA2732594A patent/CA2732594C/en not_active Expired - Fee Related
- 2009-09-16 CN CN201510373379.5A patent/CN105753988A/zh active Pending
- 2009-09-16 EP EP09778564.6A patent/EP2342234B1/en active Active
- 2009-09-16 PL PL09778564T patent/PL2342234T3/pl unknown
-
2011
- 2011-02-01 ZA ZA2011/00835A patent/ZA201100835B/en unknown
- 2011-02-02 IL IL211010A patent/IL211010A/en not_active IP Right Cessation
-
2015
- 2015-10-22 IL IL242204A patent/IL242204B/en active IP Right Grant
-
2018
- 2018-02-15 CY CY20181100189T patent/CY1119956T1/el unknown
- 2018-10-08 HK HK18112784.5A patent/HK1253579A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502938A5 (enExample) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| CN102239182B (zh) | Muc1*抗体 | |
| HRP20200591T1 (hr) | Protutijela specifična za klaudin 6 (cldn6) | |
| JP2010535713A5 (enExample) | ||
| JP2010110329A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| CA2747064C (en) | Monoclonal antibodies directed against lg4/5 domain of alpha3 chain of human laminin-5 | |
| JP2009505676A5 (enExample) | ||
| JP2010516708A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| RU2013155455A (ru) | Антитела для лечения раковых заболеваний, при которых эскспрессируется клаудин 6 | |
| JP2019536442A5 (enExample) | ||
| JP2010502220A5 (enExample) | ||
| JP2013056885A5 (enExample) | ||
| JP2013523166A5 (enExample) | ||
| JP2011130770A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2009507470A5 (enExample) | ||
| JP2005514409A (ja) | Ｍｕｃ１８抗原に対する抗体の使用 | |
| JP2009545325A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| CN104059148B (zh) | 人源化抗人表皮生长因子受体抗体及其应用 | |
| TW200918556A (en) | Treatment of tumors using specific anti-L1 antibody |